Optimizing immunotherapy with chemo-radiation for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal adenocarcinoma that is pMMR or MSS (types of tumor DNA repair).
- Your cancer is stage II or III and located in a way that matches specific tumor depth or node involvement.
- You are in good physical condition (ECOG 0 or 1) and have adequate organ function.
- You have not had previous cancer treatments like chemotherapy, radiation, or immunotherapy for this cancer.
- You do not have severe autoimmune diseases, active infections, or other serious health conditions listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial studies a shorter course of radiation for rectal cancer, followed by chemotherapy and an immune treatment called a PD-1 inhibitor. It aims to improve treatment outcomes for people with locally advanced rectal cancer that has not spread to distant organs.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.